RECURSION PHARMACEUTICALS, INC. Payments to Acquire Investments
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Payments to Acquire Investments of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-08-05
- RECURSION PHARMACEUTICALS, INC. payments to acquire investments for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. payments to acquire investments for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. payments to acquire investments for the quarter ending 2025-12-31 was $0.00.
- RECURSION PHARMACEUTICALS, INC. payments to acquire investments for the quarter ending 2025-09-30 was $2.31M.
- RECURSION PHARMACEUTICALS, INC. payments to acquire investments for fiscal 2025 was $3.81M.
- RECURSION PHARMACEUTICALS, INC. payments to acquire investments for fiscal 2024 was $0.00.
- RECURSION PHARMACEUTICALS, INC. payments to acquire investments for fiscal 2023 was $0.00.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $2.31M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-05-06 | $2.31M derived: sum of 3 quarters · filed 2026-05-06 | $2.81M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.31M derived: sum of 2 quarters · filed 2026-02-25 | $2.81M derived: sum of 3 quarters · filed 2026-08-05 | $3.81M 10-K · filed 2026-02-25 |
| 2025-09-30 | $2.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.81M derived: sum of 2 quarters · filed 2026-08-05 | $3.81M 10-Q · filed 2025-11-05 | $3.81M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.50M 10-Q · filed 2026-08-05 | $1.50M derived: sum of 3 quarters · filed 2026-08-05 | $1.50M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.00M 10-Q · filed 2026-05-06 | $1.00M derived: sum of 2 quarters · filed 2026-05-06 | $1.00M derived: sum of 3 quarters · filed 2026-05-06 | $1.00M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $0.00 10-Q · filed 2025-08-05 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-05 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |